Open AccessPharmacogenomic Analyses of Sunitinib In Patients With Pancreatic Neuroendocrine Tumors
Author(s) -
Nicola Fazio,
Jean-François Martini,
Adina Croitoru,
Michael Schenker,
Sherry Li,
Brad Rosbrook,
Kathrine C. Fernandez,
Jiří Tomášek,
Espen ThiisEvensen,
Matthew H. Kulke,
Éric Raymond
Publication year - 2019
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2018-0934
Subject(s) - medicine , sunitinib , neuroendocrine tumors , oncology , pancreatic neuroendocrine tumor , pharmacogenomics , pharmacology , cancer
Aim: Evaluate associations between clinical outcomes and SNPs in patients with well-differentiated pancreatic neuroendocrine tumors receiving sunitinib. Patients & methods: Kaplan–Meier and Cox proportional hazards models were used to analyze the association between SNPs and survival outcomes using data from a sunitinib Phase IV (genotyped, n = 56) study. Fisher’s exact test was used to analyze objective response rate and genotype associations. Results: After multiplicity adjustment, progression-free and overall survivals were not significantly correlated with SNPs; however, a higher objective response rate was significantly associated with IL1B rs16944 G/A versus G/G (46.4 vs 4.5%; p = 0.001). Conclusion: IL1B SNPs may predict treatment response in patients with pancreatic neuroendocrine tumors. VEGF pathway SNPs are potentially associated with survival outcomes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom